Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 3 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Plasma cell 3Lymphoid 2Genitourinary 2CNS 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 805Uterine Cervical Neoplasms 412Fallopian Tube Neoplasms 289Endometrial Neoplasms 287Carcinoma, Ovarian Epithelial 252Neoplasms 95Recurrence 83Breast Neoplasms 83Peritoneal Neoplasms 66Uterine Neoplasms 55Colorectal Neoplasms 55Uterine Cervical Dysplasia 50Sarcoma 49Vulvar Neoplasms 47Carcinoma, Non-Small-Cell Lung 45Neoplasm Metastasis 44Stomach Neoplasms 42Pancreatic Neoplasms 36Melanoma 34Testicular Neoplasms 32Lung Neoplasms 32Prostatic Neoplasms 29Vaginal Neoplasms 28Papillomavirus Infections 25Carcinoma 25Head and Neck Neoplasms 23Esophageal Neoplasms 23Carcinoma, Renal Cell 23Small Cell Lung Carcinoma 22Urinary Bladder Neoplasms 21

Interventions

sagopilone 1allantoicase 1Prednisolone 1BID protein, human 1Acetylcarnitine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Peripheral Nervous System Diseases × Gynecologic × Clear all
NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡